Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mahboubeh Irani, Mahdi Habibi-Anbouhi, Mahdi Behdani & Fatemeh Kazemi-Lomedasht. (2023) Targeting of human fibroblast growth factor receptor 2 by a novel specific nanobody. Preparative Biochemistry & Biotechnology 0:0, pages 1-10.
Read now
Read now
Elmira Karami, Maryam Mesbahi Moghaddam, Mahdi Behdani & Fatemeh Kazemi-Lomedasht. (2023) Effective blocking of neuropilin-1activity using oligoclonal nanobodies targeting different epitopes. Preparative Biochemistry & Biotechnology 53:5, pages 523-531.
Read now
Read now
Ayda Hassanzadeh Eskafi, Akbar Oghalaei, Fereidoun Mahboudi, Hajarsadat Ghaderi, Mahdi Behdani, Alireza Shoari & Fatemeh Kazemi-Lomedasht. (2023) Investigation of the therapeutic potential of recombinant bispecific bivalent anti-PD-L1/VEGF nanobody in inhibition of angiogenesis. Immunopharmacology and Immunotoxicology 45:2, pages 197-202.
Read now
Read now
Dang-ke Li & Guang-hui Wang. (2022) Asiaticoside reverses M2 phenotype macrophage polarization-evoked osteosarcoma cell malignant behaviour by TRAF6/NF-κB inhibition. Pharmaceutical Biology 60:1, pages 1635-1645.
Read now
Read now
Shamsi Naderi, Reyhaneh Roshan, Mahdi Behdani & Fatemeh Kazemi-Lomedasht. (2021) Inhibition of neovascularisation in human endothelial cells using anti NRP-1 nanobody fused to truncated form of diphtheria toxin as a novel immunotoxin. Immunopharmacology and Immunotoxicology 43:2, pages 230-238.
Read now
Read now
Articles from other publishers (14)
Hajarossadat Ghaderi, Atefeh Alipour, Arya Mohammadi Zadeh Holagh, Fatemeh Kazemi lomedasht, Meghdad Abdollahpour-Alitappeh, Hooman Kaghazian & Hosein Shahsavarani. (2023) Recombinant antibody fragment therapeutics: Current status and future prospects of scFv, nanobody, and mimotopes. Journal of Drug Delivery Science and Technology 89, pages 105009.
Crossref
Crossref
Rossella Di Stasi, Lucia De Rosa & Luca Domenico D’Andrea. (2023) Structure-Based Design of Peptides Targeting VEGF/VEGFRs. Pharmaceuticals 16:6, pages 851.
Crossref
Crossref
Frédéric Cawez, Paola Sandra Mercuri, Francisco Javier Morales-Yãnez, Rita Maalouf, Marylène Vandevenne, Frederic Kerff, Virginie Guérin, Jacques Mainil, Damien Thiry, Marc Saulmont, Alain Vanderplasschen, Pierre Lafaye, Gabriel Aymé, Pierre Bogaerts, Mireille Dumoulin & Moreno Galleni. (2023) Development of Nanobodies as Theranostic Agents against CMY-2-Like Class C β-Lactamases. Antimicrobial Agents and Chemotherapy 67:4.
Crossref
Crossref
Elmira Karami, Parisa Azizi, Mahdi Behdani & Fatemeh Kazemi-Lomedasht. (2023) Efficient Inhibition of Pathologic Angiogenesis using Combination Therapy of
Anti-Epcam and Anti-VEGFR2 Nanobodies. Current Pharmaceutical Design 29:13, pages 1059-1066.
Crossref
Crossref
Reyhaneh Roshan, Shamsi Naderi, Mahdi Behdani, Reza Ahangari Cohan & Fatemeh Kazemi-Lomedasht. (2022) A Novel Immunotoxin Targeting Epithelial Cell Adhesion Molecule Using Single Domain Antibody Fused to Diphtheria Toxin. Molecular Biotechnology.
Crossref
Crossref
Hantao Lou & Xuetao Cao. (2022) Antibody variable region engineering for improving cancer immunotherapy. Cancer Communications 42:9, pages 804-827.
Crossref
Crossref
Alireza Shoari, Mehdi Tahmasebi, Farnaz Khodabakhsh, Reza Ahangari Cohan, Akbar Oghalaie & Mahdi Behdani. (2022) Angiogenic biomolecules specific nanobodies application in cancer imaging and therapy; review and updates. International Immunopharmacology 105, pages 108585.
Crossref
Crossref
Kevin Van holsbeeck, José C. Martins & Steven Ballet. (2022) Downsizing antibodies: Towards complementarity-determining region (CDR)-based peptide mimetics. Bioorganic Chemistry 119, pages 105563.
Crossref
Crossref
Elmira Karami, Shamsi Naderi, Reyhaneh Roshan, Mahdi Behdani & Fatemeh Kazemi-Lomedasht. (2022) Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies. Cancer Chemotherapy and Pharmacology 89:2, pages 165-172.
Crossref
Crossref
Dina Ahmed, Hima Puthussery, Pooja Basnett, Jonathan C. Knowles, Sigrun Lange & Ipsita Roy. (2021) Controlled Delivery of Pan-PAD-Inhibitor Cl-Amidine Using Poly(3-Hydroxybutyrate) Microspheres. International Journal of Molecular Sciences 22:23, pages 12852.
Crossref
Crossref
Jacek Siewiera, Michał Smoleński, Natalia Jermakow, Jacek Kot, Klaudia Brodaczewska, Jacek Turyn, Magdalena A. Zabielska-Kaczorowska, Nils Ludwig & Mirosław J. Szczepański. (2021) Effect of Hyperbaric Oxygenation on Blood Cytokines and Arginine Derivatives; No Evidence for Induction of Inflammation or Endothelial Injury. Journal of Clinical Medicine 10:23, pages 5488.
Crossref
Crossref
Xiaoqing Ye, Jean-François Gaucher, Michel Vidal & Sylvain Broussy. (2021) A Structural Overview of Vascular Endothelial Growth Factors Pharmacological Ligands: From Macromolecules to Designed Peptidomimetics. Molecules 26:22, pages 6759.
Crossref
Crossref
Jafar Sharifi, Mohammad Reza Khirehgesh, Bahman Akbari, Bijan Soleymani & Kamran Mansouri. (2021) Paper Title “Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody”. Molecular Biotechnology 63:6, pages 525-533.
Crossref
Crossref
Shamsi Naderi, Reyhaneh Roshan, Hajarsadat Ghaderi, Mahdi Behdani, Sara Mahmoudi, Mahdi Habibi-Anbouhi, Mohammad Ali Shokrgozar & Fatemeh Kazemi-Lomedasht. (2020) Selection and characterization of specific nanobody against neuropilin-1 for inhibition of angiogenesis. Molecular Immunology 128, pages 56-63.
Crossref
Crossref